OZAMBRIS Trademark

Trademark Overview

On Thursday, October 6, 2016, a trademark application was filed for OZAMBRIS with the United States Patent and Trademark Office. The USPTO has given the OZAMBRIS trademark a serial number of 87195494. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 20, 2017. This trademark is owned by Eli Lilly and Company. The OZAMBRIS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, Parkinson's disease, psychiatric disorders, sleep disorders, urological disorders; antidepressants; Diagnostic agents and substances for medical purposes; radiopharmaceutic...
ozambris

General Information

Serial Number87195494
Word MarkOZAMBRIS
Filing DateThursday, October 6, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 20, 2017
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 21, 2017

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, Parkinson's disease, psychiatric disorders, sleep disorders, urological disorders; antidepressants; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 13, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285
Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events

Event DateEvent Description
Monday, November 20, 2017ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, November 20, 2017ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 18, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 21, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 21, 2017PUBLISHED FOR OPPOSITION
Wednesday, February 1, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 18, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, January 14, 2017ASSIGNED TO EXAMINER
Thursday, October 13, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, October 10, 2016NEW APPLICATION ENTERED IN TRAM

Related Keywords

ozambris disorders diseases pharmaceutical preparations neurodegenerative muscle pain pancreatic neurological metabolic